DDrare: Database of Drug Development for Rare Diseases

Searched query = "Lennox-Gastaut syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Any other approved Antiepileptic Drug; CANNABIDIOL; CBD; CBD - Oral Solution, is known as Epidiolex, and is the approved name in the USA.; CLOBAZAM; Cannabidiol; Cannabidiol (CBD); Cannabidiol Oral Solution; Carisbamate; Clobazam; Clobazam High Dose; Clobazam Low Dose; Clobazam Medium Dose; Clobazam PhEur; Clobazam Pheur; Clobazam Tablets; Clobazam Tablets 10mg; Clobazam Tablets 20mg; Clobazam Tablets 5mg; E2007; E2080; EZOGABINE (US ONLY); EZOGABINE (US only); Ezogabine; Ezogabine/retigabine; FENFLURAMINE HYDROCHLORIDE; Fenfluramine; Fenfluramine HCl, DL-Fenfluramine, (±)-Fenfluramine; Fenfluramine hydrochloride (colorless); Fycompa; GW582892; GWP42003-P; GWP42003-P 20 mg/kg/day Dose; Inovelon; Investigators Choice of Approved AED; Investigators choice of approved AEDs; Lamictal; Lamotrigine; Melatonin; PERAMPANEL; Perampanel; Placebo; Potiga; Procedure: 12-Lead ECG; RETIGABINE; RETIGABINE/EZOGABINE; RUFINAMIDE; Retigabine; Retigabine/Ezogabine; Retigabine/ezogabine; Rufinamide; Rufinamide (E2080); Rufinamide oral suspension; Sodio valproato; TAK-935; Topimarate; Topimarato; Topiramate; Turmeric; ZX008; ZX008 (Fenfluramine Hydrochloride); ZX008 0.2 and 0.8 mg/kg/day; ZX008 0.2 or 0.8 mg/kg/day

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00518713 (ClinicalTrials.gov)	August 2007	20/8/2007	Clobazam in Patients With Lennox-Gastaut Syndrome	Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam in Patients With Lennox-Gastaut Syndrome	Epilepsy;Epilepsy, Generalized;Seizures	Drug: Clobazam Low Dose;Drug: Clobazam Medium Dose;Drug: Clobazam High Dose;Drug: Placebo	Lundbeck LLC	NULL	Completed	2 Years	60 Years	All	238	Phase 3	United States;Australia;Belarus;India;Lithuania;Serbia
2	NCT00162981 (ClinicalTrials.gov)	October 2005	9/9/2005	Clobazam in Subjects With Lennox-Gastaut Syndrome	Safety and Efficacy of Clobazam in Subjects With Lennox-Gastaut Syndrome	Epilepsy;Epilepsy, Generalized;Seizures	Drug: Clobazam Low Dose;Drug: Clobazam High Dose	Lundbeck LLC	NULL	Completed	2 Years	30 Years	All	68	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00518713
(ClinicalTrials.gov)

August 2007

20/8/2007

Clobazam in Patients With Lennox-Gastaut Syndrome

Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam in Patients With Lennox-Gastaut Syndrome

Epilepsy;Epilepsy, Generalized;Seizures

Drug: Clobazam Low Dose;Drug: Clobazam Medium Dose;Drug: Clobazam High Dose;Drug: Placebo

Lundbeck LLC

NULL

Completed

2 Years

60 Years

All

238

Phase 3

United States;Australia;Belarus;India;Lithuania;Serbia

NCT00162981
(ClinicalTrials.gov)

October 2005

9/9/2005

Clobazam in Subjects With Lennox-Gastaut Syndrome

Safety and Efficacy of Clobazam in Subjects With Lennox-Gastaut Syndrome

Epilepsy;Epilepsy, Generalized;Seizures

Drug: Clobazam Low Dose;Drug: Clobazam High Dose

Lundbeck LLC

NULL

Completed

2 Years

30 Years

All

Phase 2

United States